Adam Steensberg, Zealand Pharma CEO

Fol­low­ing luke­warm launch and lay­offs, Zealand Phar­ma is li­cens­ing out its di­a­betes drug to No­vo Nordisk

In March, Zealand Phar­ma gut­ted its US work­force and said it was look­ing for strate­gic part­ner­ships for its di­a­betes prod­ucts fol­low­ing a dis­ap­point­ing first year …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.